Key result
New oral anticoagulants, including direct thrombin and factor Xa inhibitors, have emerged as attractive alternatives to warfarin for stroke prevention in atrial fibrillation.
Why the study?
Do oral direct thrombin inhibitors and direct factor Xa inhibitors prevent stroke in patients with atrial fibrillation compared to warfarin?
Population
Patients with atrial fibrillation
Comparison
Oral direct thrombin inhibitors and direct… vs Warfarin
Design
Review
Authors
Loading...
Supports NOAC consideration in eligible AF patients; leaves long-term real-world efficacy and safety open for evaluation.
Do oral direct thrombin inhibitors and direct factor Xa inhibitors prevent stroke in patients with atrial fibrillation compared to warfarin?
New oral anticoagulants offer important advantages over warfarin for stroke prevention in atrial fibrillation, but real-world long-term data is still needed.
Potpara et al. (2012) conducted a review in atrial fibrillation. New oral anticoagulants (direct thrombin inhibitors and direct factor Xa inhibitors) vs. Warfarin was evaluated on Stroke prevention. New oral anticoagulants, including direct thrombin and factor Xa inhibitors, have emerged as attractive alternatives to warfarin for stroke prevention in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: